Document Detail

Using point-of-care CD34 enumeration to optimize PBSC collection conditions.
MedLine Citation:
PMID:  12028839     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: A PBSC graft containing 4-5 x 10(6) CD34(+) cells/kg is considered optimal in terms of durable engraftment. Tracking CD34 kinetics via point-of-care testing during PBSC mobilization could determine which (and when) patients will yield an optimal product. We evaluated whether microvolume fluorimetry (MVF) would be useful in optimizing PBSC mobilization/harvest and if it will shorten our standard 6 h collection. METHODS: Absolute CD34 values were obtained using the IMAGN 2000 and STELLer CD34 assay (50 microL sample volume). Peripheral blood (PB) CD34 values from 30 patients undergoing PBSC mobilization were used to generate a PB CD34-based algorithm that would predict collection day/duration of apheresis. The algorithm was then used prospectively to collect PBSC products on 50 hematologic malignancy (HM) patients. RESULTS: Using the algorithm, patients were assigned to either a 6 (11-20 CD34/microL), 4 (21-49 CD34/microL) or 2 (> or = 50 CD34/microL) h collection. Patients with a CD34 value < or = 10/microL were re-tested. All patients (n = 43) predicted to mobilize reached the optimal CD34 (4-5 x 10(6)/kg) value with 1.0 apheresis procedure; seven patients had < or = 10/microL (nonmobilizers). The majority (75%) had apheresis charges decreased by 33-66%; 47% only required a 2 h procedure and 28% required 4 h. All patients demonstrated rapid trilineage engraftment. DISCUSSION: Absolute PB CD34 measurement using MVF offers a rapid and reliable approach to obtaining optimal PBSC products with minimal technical expertise. Although not a replacement for conventional flow cytometry, it meets the requirements for a point-of-care procedure.
S J Noga; G B Vogelsang; S C Miller; S Meusel; K Loper; R Case; B Myers; L Rogers; I Flinn; M Borowitz; P O'Donnell
Related Documents :
24216059 - Identification and characterisation of osteoarthritis patients with inflammation derive...
11092099 - Anticoagulants.
11893129 - The frequency and effects of cytochrome p450 (cyp) 2c9 polymorphisms in patients receiv...
24316139 - Histological characteristics of vaginal cuff tissue from patients with vaginal cuff deh...
19626689 - New onset atrial fibrillation after patent foramen ovale closure.
8076119 - Right atrial isolation associated with atrial septal closure in patients with atrial se...
24183309 - Assessment of interferon-related biomarkers in aicardi-goutières syndrome associated wi...
21959689 - Long-term outcomes after transoral incisionless fundoplication in patients with gerd an...
18204369 - Jaccoud arthropathy in systemic lupus erythematosus: analysis of clinical characteristi...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cytotherapy     Volume:  3     ISSN:  1465-3249     ISO Abbreviation:  Cytotherapy     Publication Date:  2001  
Date Detail:
Created Date:  2002-05-24     Completed Date:  2003-01-22     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  100895309     Medline TA:  Cytotherapy     Country:  England    
Other Details:
Languages:  eng     Pagination:  11-8     Citation Subset:  IM    
The Johns Hopkins Hematopoietic and Therapeutic Support Service, Baltimore, MD 21205, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD34 / analysis*
Blood Component Removal / methods*
Erythroid Precursor Cells / transplantation*
Fluorometry / methods
Hematologic Neoplasms / blood,  therapy
Hematopoietic Stem Cell Mobilization / methods*
Point-of-Care Systems*
Time Factors
Treatment Outcome
Grant Support
Reg. No./Substance:
0/Antigens, CD34

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Accurate calculation of blood volume to be processed by apheresis to achieve target CD34+ cell numbe...
Next Document:  Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer...